Press ReleasesBack to Press Releases
Sigilon Therapeutics to Present at Cowen & Company 38th Annual Health Care Conference
CAMBRIDGE, Mass., March 9, 2018 – Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that the company will present at the following upcoming conference. Presentation details are as follows:
Cowen & Company 38th Annual Health Care Conference
Presenter: Paul Wotton, Ph.D., Chief Executive Officer
Date: Monday, March 12, 2018
Time: 10 a.m. EDT
Location: Boston Marriott Copley Place
About Sigilon Therapeutics
Founded and created by Flagship Pioneering, Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics’ Afibromer™ technology platform include cell implants that act as responsive “living therapeutics,” providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.
For more information please visit www.sigilon.com or follow on Twitter at https://twitter.com/Sigilon_Inc.
Rich Allan or David Schull
Russo Partners, LLC